Journal
ONCOGENE
Volume 27, Issue 51, Pages 6550-6560Publisher
NATURE PUBLISHING GROUP
DOI: 10.1038/onc.2008.255
Keywords
PDGFR-A; therapeutic target; alveolar rhabdomyosarcoma
Funding
- NIH [RO1CA 133229]
- University Research Council (UTHSCSA)
- Sarcoma Foundation of America
- Amschwand Sarcoma Cancer Foundation
- National Cancer Institute Center
- San Antonio Cancer Center [P30 CA54174]
Ask authors/readers for more resources
Alveolar rhabdomyosarcoma is an aggressive skeletal muscle cancer of childhood. Our initial studies of rhabdomyosarcoma gene expression for patients enrolled in a national clinical trial suggested that platelet-derived growth factor receptor A (PDGFR-A) may be a mediator of disease progression and metastasis. Using our conditional mouse tumor models that authentically recapitulate the primary mutations and metastatic progression of alveolar rhabdomyosarcomas in humans, we found by immunoblotting and immunokinase assays that PDGFR-A and its downstream effectors, mitogen-activated protein kinase and Akt, were highly activated in both primary and metastatic tumors. Inhibition of PDGFR-A by RNA interference, small molecule inhibitor or neutralizing antibody had a dramatic effect on tumor cell growth both in vitro and in vivo, although resistance evolved in one-third of tumors. These results establish proof-of-principal for PDGFR-A as a therapeutic target in alveolar rhabdomyosarcoma.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available